Biogen's stock is being evaluated by analysts and investors, with some considering whether to buy, hold, or sell the stock. The company has recently had its alzheimer's treatment cleared for at-home use by the FDA, which has led to some analysts raising their price targets and the stock price increasing. However, there are also investigations and uncertainties surrounding the company, including its growth outlook and valuation, that may be impacting investment decisions.